Published in J Clin Oncol on May 01, 1995
Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med (1999) 11.58
Random allocation or allocation at random? Patients' perspectives of participation in a randomised controlled trial. BMJ (1998) 4.79
The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals. BMJ (1998) 3.15
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Subjects' expectations in neuroimaging research. J Magn Reson Imaging (2006) 2.22
Mindsets, informed consent, and research. Hastings Cent Rep (2013) 2.16
Communication and informed consent in phase 1 trials: a review of the literature. Support Care Cancer (2006) 2.12
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer (2012) 1.94
Consenting of the vulnerable: the informed consent procedure in advanced cancer patients in Mexico. BMC Med Ethics (2006) 1.93
The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer (2010) 1.84
Unrealistic optimism in early-phase oncology trials. IRB (2011) 1.75
Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer (2005) 1.71
Satisfaction with the decision to participate in cancer clinical trials is high, but understanding is a problem. Support Care Cancer (2010) 1.69
Strategies to minimize risks and exploitation in phase one trials on healthy subjects. Am J Bioeth (2006) 1.65
Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health Soc Work (2013) 1.59
Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs (2007) 1.44
Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol (2010) 1.42
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer (2006) 1.41
Communication about cancer near the end of life. Cancer (2008) 1.40
Does random treatment assignment cause harm to research participants? PLoS Med (2006) 1.39
Participants' understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bull World Health Organ (2015) 1.34
Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making (2008) 1.34
Development of a measure to assess patient trust in medical researchers. Ann Fam Med (2006) 1.30
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res (2012) 1.29
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer (2003) 1.25
Drivers and barriers to patient participation in RCTs. Br J Cancer (2013) 1.19
Emerging empirical evidence on the ethics of schizophrenia research. Schizophr Bull (2005) 1.16
Informed consent in psychiatry clinical research: A conceptual review of issues, challenges, and recommendations. Perspect Clin Res (2012) 1.16
What are terminally ill cancer patients told about their expected deaths? A study of cancer physicians' self-reports of prognosis disclosure. J Clin Oncol (2008) 1.15
Communicating and understanding the purpose of pediatric phase I cancer trials. J Clin Oncol (2012) 1.14
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs (2009) 1.12
Oncologists' recommendations of clinical trial participation to patients. Patient Educ Couns (2007) 1.12
Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations. J Clin Oncol (2008) 1.12
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? J Clin Oncol (2012) 1.11
Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis. J Med Ethics (2005) 1.09
Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics (2008) 1.08
Willingness of subjects with thought disorder to participate in research. Schizophr Bull (2005) 1.04
Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist (2011) 1.02
Associations among awareness of prognosis, hopefulness, and coping in patients with advanced cancer participating in phase I clinical trials. Support Care Cancer (2003) 1.00
Evaluation of an educational program to improve communication with patients about early-phase trial participation. Oncologist (2012) 1.00
Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations. Br J Cancer (1997) 0.99
Factors influencing physician referrals of patients to clinical trials. J Natl Med Assoc (2008) 0.97
"Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents. Invest New Drugs (2009) 0.96
Using formative research to develop a context-specific approach to informed consent for clinical trials. J Empir Res Hum Res Ethics (2006) 0.94
Are there adverse consequences of quizzing during informed consent for HIV research? J Med Ethics (2011) 0.93
Ethical Issues in Deep Brain Stimulation Research for Treatment-Resistant Depression: Focus on Risk and Consent. AJOB Neurosci (2015) 0.93
The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. Support Care Cancer (2007) 0.93
Phase I participants' views of quality of life and trial participation burdens. Support Care Cancer (2007) 0.92
Benefits and burdens of placebos in psychiatric research. Psychopharmacology (Berl) (2003) 0.91
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol (2014) 0.90
Clinical trial participation as part of end-of-life cancer care: associations with medical care and quality of life near death. J Pain Symptom Manage (2013) 0.90
Phase I oncology trials: why the therapeutic misconception will not go away. J Med Ethics (2006) 0.90
Traditional roles in a non-traditional setting: genetic counseling in precision oncology. J Genet Couns (2014) 0.90
A pilot study of simple interventions to improve informed consent in clinical research: feasibility, approach, and results. Clin Trials (2014) 0.89
Quality of life and understanding of disease status among cancer patients of different ethnic origin. Br J Cancer (2003) 0.88
Promoting Factors and Barriers to Participation in Early Phase Clinical Trials: Patients Perspectives. J Community Med Health Educ (2014) 0.88
Ethical issues in the development of new agents. Invest New Drugs (1999) 0.88
Beliefs and practices of patients with advanced cancer: implications for communication. Br J Cancer (2004) 0.88
Improving participant understanding of informed consent in an HIV-prevention clinical trial: a comparison of methods. AIDS Behav (2012) 0.88
Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study. Cancer (2010) 0.88
A phase I trial on the ethics of phase I trials. J Clin Oncol (1995) 0.88
Pediatric data sharing in genomic research: attitudes and preferences of parents. Pediatrics (2014) 0.87
The acceptability and impact of a randomised controlled trial of welfare rights advice accessed via primary health care: qualitative study. BMC Public Health (2006) 0.87
Patients' perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis. J Med Life (2010) 0.87
Early Phase Clinical Trials: Referral Barriers and Promoters among Physicians. J Community Med Health Educ (2012) 0.85
Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers. Eur J Cancer Care (Engl) (2014) 0.85
The ethics of research on deep brain stimulation for depression: decisional capacity and therapeutic misconception. Ann N Y Acad Sci (2012) 0.84
Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials (2016) 0.83
Research biopsies in phase I studies: views and perspectives of participants and investigators. IRB (2012) 0.83
Perceptions and referral trends into phase I oncology trials: results of a clinical survey. J Oncol (2011) 0.83
Beyond the question of placebo controls: ethical issues in psychopharmacological drug studies. Psychopharmacology (Berl) (2003) 0.82
Description of the types and content of phase 1 clinical trial consent conversations in practice. Clin Trials (2015) 0.82
Evaluation of patient enrollment in oncology phase I clinical trials. Oncologist (2013) 0.81
Giving voice to study volunteers: comparing views of mentally ill, physically ill, and healthy protocol participants on ethical aspects of clinical research. J Psychiatr Res (2014) 0.81
Parents' online portrayals of pediatric treatment and research options. J Empir Res Hum Res Ethics (2009) 0.81
Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat (2013) 0.81
A Web-based communication aid for patients with cancer: the CONNECT Study. Cancer (2013) 0.81
Distress among caregivers of phase I trial participants: a cross-sectional study. Support Care Cancer (2014) 0.80
Legitimate requests and indecent proposals: matters of justice in the ethical assessment of phase I trials involving competent patients. J Med Ethics (2005) 0.80
Communication about the risks and benefits of phase I pediatric oncology trials. Contemp Clin Trials (2015) 0.79
Therapeutic Misconception in Psychiatry Research: A Systematic Review. Clin Psychopharmacol Neurosci (2016) 0.78
Views of people with schizophrenia regarding aspects of research: study size and funding sources. Schizophr Bull (2005) 0.78
Participants' Perceptions of Deep Brain Stimulation Research for Treatment-Resistant Depression: Risks, Benefits, and Therapeutic Misconception. AJOB Prim Res (2011) 0.78
The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer. Am J Clin Oncol (2016) 0.78
Regulatory and ethical issues for phase I in utero gene transfer studies. Hum Gene Ther (2011) 0.78
"Until the trial is complete you can't really say whether it helped you or not, can you?": exploring cancer patients' perceptions of taking part in a trial of acupressure wristbands. BMC Complement Altern Med (2013) 0.78
Cancer clinical trial participants' assessment of risk and benefit. AJOB Empir Bioeth (2015) 0.77
Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisited. Front Pharmacol (2013) 0.77
A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: early stopping for lack of efficacy. Clin Trials (2012) 0.77
Understanding clinical trials in childhood cancer. Paediatr Child Health (2006) 0.77
Placebo-controlled trials: good science or medical neglect? West J Med (2000) 0.77
Research biopsies in the context of early phase oncology studies: clinical and ethical considerations. Oncol Rev (2013) 0.77
Communicating about phase I trials: objective disclosures are only a first step. Oncologist (2012) 0.76
The evaluation of the risks and benefits of phase II cancer clinical trials by institutional review board (IRB) members: a case study. J Med Ethics (2006) 0.76
Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data. BMC Cancer (2016) 0.75
Abortion decisions as inclusion and exclusion criteria in research involving pregnant women and fetuses. J Med Ethics (2011) 0.75
Assent Described: Exploring Perspectives From the Inside. J Pediatr Nurs (2016) 0.75
An exploratory study of therapeutic misconception among incarcerated clinical trial participants. AJOB Empir Bioeth (2015) 0.75
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep (2016) 0.75
Readability and Content Assessment of Informed Consent Forms for Phase II-IV Clinical Trials in China. PLoS One (2016) 0.75
An alternative strategy for studying adverse events in medical care. Lancet (1997) 5.98
Sounding Boards. Confidentiality in medicine--a decrepit concept. N Engl J Med (1982) 5.00
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
The rise and fall of the futility movement. N Engl J Med (2000) 4.88
Effects of organizational change in the medical intensive care unit of a teaching hospital: a comparison of 'open' and 'closed' formats. JAMA (1996) 4.71
Basic curricular goals in medical ethics. N Engl J Med (1985) 4.03
Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet (1997) 3.77
Community hospital ethics consultation: evaluation and comparison with a university hospital service. Am J Med (1992) 3.30
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther (2012) 3.15
Beyond autonomy--physicians' refusal to use life-prolonging extracorporeal membrane oxygenation. N Engl J Med (1993) 2.96
Physicians' attitudes about the care of patients in the persistent vegetative state: a national survey. Ann Intern Med (1996) 2.85
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J (2002) 2.77
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol (1998) 2.69
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest (1998) 2.62
Transplantation of liver grafts from living donors into adults--too much, too soon. N Engl J Med (2001) 2.61
Should alcoholics compete equally for liver transplantation? JAMA (1991) 2.61
What are the goals of ethics consultation? A consensus statement. J Clin Ethics (1996) 2.59
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst (1993) 2.57
Ethics of liver transplantation with living donors. N Engl J Med (1989) 2.47
Beyond advance directives--health care surrogate laws. N Engl J Med (1992) 2.26
Searching for moral certainty in medicine: a proposal for a new model of the doctor-patient encounter. Bull N Y Acad Med (1981) 2.25
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Paradoxes in cancer patients' advance care planning. J Palliat Med (2000) 2.11
Elective surgical patients as living organ donors: a clinical and ethical innovation. Am J Transplant (2009) 2.02
A legacy of Osler. Teaching clinical ethics at the bedside. JAMA (1978) 1.95
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther (1999) 1.94
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res (2000) 1.93
Ethics consultants' recommendations for life-prolonging treatment of patients in a persistent vegetative state. JAMA (1993) 1.91
Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther (2007) 1.90
Oral chemotherapy: rationale and future directions. J Clin Oncol (1998) 1.88
Long terminal repeat sequences impart hematopoietic transformation properties to the myeloproliferative sarcoma virus. Proc Natl Acad Sci U S A (1985) 1.88
Clinical ethics consultation: Godsend or "God squad"? Am J Med (1988) 1.86
The return of research results to participants: pilot questionnaire of adolescents and parents of children with cancer. Pediatr Blood Cancer (2007) 1.83
An ethics consultation service in a teaching hospital. Utilization and evaluation. JAMA (1988) 1.80
Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am (1997) 1.80
Euthanasia--a critique. N Engl J Med (1990) 1.77
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol (2000) 1.74
The illusion of futility in clinical practice. Am J Med (1989) 1.73
The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res (1995) 1.73
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res (1994) 1.72
'Doctors must not kill'. JAMA (1988) 1.71
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
Ethical issues in growth hormone therapy. JAMA (1989) 1.69
Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol (1999) 1.69
Life-sustaining treatment. A prospective study of patients with DNR orders in a teaching hospital. Arch Intern Med (1988) 1.68
Functional analysis of a retroviral host-range mutant: altered long terminal repeat sequences allow expression in embryonal carcinoma cells. Proc Natl Acad Sci U S A (1987) 1.68
Informed consent in emergency research. Prehospital thrombolytic therapy for acute myocardial infarction. JAMA (1989) 1.67
Teaching clinical ethics. J Clin Ethics (1990) 1.67
The ethical assessment of innovative therapies: liver transplantation using living donors. Theor Med (1990) 1.67
Ethics of a paired-kidney-exchange program. N Engl J Med (1997) 1.66
Use of the Hippocratic Oath: a review of twentieth century practice and a content analysis of oaths administered in medical schools in the U.S. and Canada in 1993. J Clin Ethics (1997) 1.64
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB (2001) 1.62
Dialysis decision making in Canada, the United Kingdom, and the United States. Am J Kidney Dis (1998) 1.60
Retroviral mutants efficiently expressed in embryonal carcinoma cells. Proc Natl Acad Sci U S A (1986) 1.60
Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol (1989) 1.57
Autocrine stimulation after transfer of the granulocyte/macrophage colony-stimulating factor gene and autonomous growth are distinct but interdependent steps in the oncogenic pathway. Proc Natl Acad Sci U S A (1987) 1.57
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer (1997) 1.57
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol (2000) 1.56
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther (2012) 1.55
The morning-report syndrome and medical search. N Engl J Med (1979) 1.53
Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood (1994) 1.53
Ethical considerations for participation of nondirected living donors in kidney exchange programs. Am J Transplant (2010) 1.51
Unilateral do-not-attempt-resuscitation orders and ethics consultation: a case series. Crit Care Med (1999) 1.49
Talking to comatose patients. Arch Neurol (1988) 1.48
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest (1999) 1.47
99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J Nucl Med (1999) 1.46
Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res (1996) 1.44
Clinical medical ethics. J Clin Ethics (1990) 1.44
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood (1990) 1.44
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol (1994) 1.44
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst (1994) 1.44
Equipoise and the ethics of segmental liver transplantation. Clin Res (1988) 1.44
Host cis-mediated extinction of a retrovirus permissive for expression in embryonal stem cells during differentiation. J Virol (1998) 1.42
Anticancer drug discovery and development throughout the world. J Clin Oncol (2002) 1.42
Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol (1995) 1.42
Continuous propofol infusion for the relief of treatment-resistant discomfort in a terminally ill pediatric patient with cancer. J Pediatr Hematol Oncol (1996) 1.42
What does Cruzan mean to the practicing physician? Arch Intern Med (1991) 1.41
What transplantation can teach us about health care reform. The Ethics and Social Impact Committee. N Engl J Med (1994) 1.40
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. Ann Oncol (1999) 1.40
Growth of a new intrarenal lesion in the remaining kidney of a patient with bilateral nephroblastomatosis and a previous nephrectomy for Wilms tumor. Med Pediatr Oncol (2000) 1.39
Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme. Cancer Invest (1995) 1.39
A right to health care: ambiguity, professional responsibility, and patient liberty. J Med Philos (1979) 1.37
Amyotrophic lateral sclerosis and life-sustaining therapy: patients' desires for information, participation in decision making, and life-sustaining therapy. Mayo Clin Proc (1991) 1.37
Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs (2001) 1.35
Bone marrow transplantation for sickle cell disease. A study of parents' decisions. N Engl J Med (1991) 1.33
Point mutations in the U3 region of the long terminal repeat of Moloney murine leukemia virus determine disease specificity of the myeloproliferative sarcoma virus. Virology (1986) 1.30
Metaphors and models of doctor-patient relationships: their implications for autonomy. Theor Med (1984) 1.30
Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med (2006) 1.29
Viral transfer, transcription, and rescue of a selectable myeloproliferative sarcoma virus in embryonal cell lines: expression of the mos oncogene. Mol Cell Biol (1986) 1.29
Legalized active euthanasia: an Aesculapian tragedy. Bull Am Coll Surg (1989) 1.29
Requirements for ethics, socioeconomic, and legal education in postgraduate medical programs. J Clin Ethics (1993) 1.27
Ethics committees: decisions by bureaucracy. Hastings Cent Rep (1986) 1.27
Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol (1991) 1.26
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood (2000) 1.26